Passage BIO Inc
For the period ended Dec 31, 2024. Filed Mar 4, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 4, 2025
PASG$3.43-13.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended | ||||||
| · · December 31, | ||||||
| (in thousands) · 2024 · 2023 | ||||||
| Cash flows used in operating activities: · · | ||||||
| Net loss | | $(64,767) | | $(102,062) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | | | | |||
| Depreciation and amortization | | 3,081 | | 3,721 | ||
| Share‑based compensation | | 5,820 | | 10,921 | ||
| Amortization of premium and discount on marketable securities, net | | | (1,527) | | | (2,036) |
| Loss on disposal of property and equipment | | — | | 463 | ||
| Impairment of long-lived assets | | | 5,233 | | 5,390 | |
| Changes in operating assets and liabilities: | | | | |||
| Prepaid expenses and other current assets, and other assets | | 255 | | 3,837 | ||
| Prepaid research and development | | 1,521 | | 3,766 | ||
| Non-refundable sublicense and transition services payments received | | | 8,226 | | | — |
| Right of use assets and operating lease liabilities | | | (279) | | | (133) |
| Accounts payable | | (556) | | (2,790) | ||
| Accrued expenses and other current liabilities | | (4,963) | | 659 | ||
| Net cash provided by (used in) operating activities | | (47,956) | | (78,264) | ||
| Cash flows provided by (used in) investing activities: | | | ||||
| Purchases of marketable securities | | (88,170) | | (129,432) | ||
| Sales or maturities of marketable securities | | 143,150 | | 194,815 | ||
| Purchases of property and equipment | | (34) | | (146) | ||
| Net cash provided by (used in) investing activities | | 54,946 | | 65,237 | ||
| Cash flows provided by (used in) financing activities: | | | ||||
| Proceeds from issuance of common stock under the ATM Facility, net of offering costs | | | 8,742 | | | — |
| Proceeds from the exercise of stock options | | 35 | | — | ||
| Proceeds from the issuance of common stock under employee stock purchase plan | | | 97 | | | 135 |
| Net cash provided by (used in) financing activities | | 8,874 | | 135 | ||
| Net increase (decrease) in cash and cash equivalents | | 15,864 | | (12,892) | ||
| Cash and cash equivalents at beginning of year | | 21,709 | | 34,601 | ||
| Cash and cash equivalents at end of year | | $37,573 | | $21,709 | ||
| Supplemental disclosure of non‑cash investing and financing activities: | | | ||||
| Unrealized gain (loss) on marketable securities | | $51 | | $923 | ||
| Property and equipment in accounts payable and accrued expenses and other current liabilities | | $— | | $23 | ||
| Right of use assets recognized upon the commencement of sublease | | $(422) | | $— | ||
| Operating lease liabilities recognized upon the commencement of sublease | | $422 | | $— | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.